Your shopping cart is currently empty

ZYZ-488 is an Apoptotic Protease-Activating Factor 1 (Apaf-1) inhibitor that inhibits the activation of procaspase-9 and procaspase-3. It can be used to study cardiovascular diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $297 | 6-8 weeks | 6-8 weeks | |
| 25 mg | $987 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,360 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $1,860 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $365 | 6-8 weeks | 6-8 weeks |
| Description | ZYZ-488 is an Apoptotic Protease-Activating Factor 1 (Apaf-1) inhibitor that inhibits the activation of procaspase-9 and procaspase-3. It can be used to study cardiovascular diseases. |
| In vitro | ZYZ-488 is a novel inhibitor of apoptotic protease activator 1 (Apaf-1). The main mechanism is that ZYZ-488 binds directly to Apaf-1, thus blocking the recruitment of procaspase-9 by Apaf-1. [1] |
| In vivo | Intramuscular injection of ZYZ-488 (33.9 mg/kg or 67.8 mg/kg) in mice reduced the MI-induced increase in left ventricular volume and reduced the thickness of the ventricular wall. ZYZ-488 preserves cardiac function in a dose-dependent manner. [1] [2] |
| Synonyms | ZYZ488 |
| Molecular Weight | 487.46 |
| Formula | C20H29N3O11 |
| Cas No. | 1470302-79-4 |
| Smiles | O(C1=C(OC)C=C(C(OCCCCNC(=N)N)=O)C=C1OC)[C@@H]2O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]2O |
| Relative Density. | 1.57 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 80 mg/mL (164.12 mM), Sonication is recommended. DMSO: 180 mg/mL (369.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.26 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.